Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: first-dose orthostatic hypotension, palpitations, angina, edema, syncope.
EENT: blurred vision, intraoperative floppy iris syndrome.
GI: abdominal cramps, diarrhea, dry mouth, nausea, vomiting.
GU: erectile dysfunction, priapism.
Neuro: dizziness, headache, weakness, depression, drowsiness.
Drug-Drug:
Hypertension
Benign Prostatic Hyperplasia
Therapeutic Classification: antihypertensives
Pharmacologic Classification: peripherally acting antiadrenergics
Absorption: 60% absorbed following oral administration.
Distribution: Widely distributed.
Protein Binding: 97%.
Metabolism/Excretion: Extensively metabolized by the liver. Minimal (5–10%) renal excretion of unchanged drug.
Half-life: 2–3 hr.
(antihypertensive effects)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 2 hr | 2–4 hr† | 10 hr |
†Following single dose; maximal antihypertensive effects occur after 3–4 wk of chronic dosing.
NDC Code*
